QP-Brain®

by Quibim S.L.  · Based in Spain →The evolution in brain MRI analysis for early disease detection.
Neurology Radiology

Contact vendor
Regulatory Status Disclosed

Overview

QP-Brain® is an AI-powered medical imaging processing application developed by Quibim S.L. designed to enhance magnetic resonance imaging (MRI) analysis of the brain, particularly in the context of an aging population and the increasing prevalence of neurodegenerative diseases.

The software provides quantitative analysis of patients’ brain MRI scans, delivering automatic quantification and display of imaging findings and data. It precisely measures absolute and relative volumes of grey and white matter, cerebrospinal fluid, and analyzes 132 distinct brain regions (left/right). QP-Brain® also identifies and quantifies White Matter Hyperintensities (WMH) load and location, utilizing 2D FLAIR input.

By comparing this quantitative data with an extensive normative database, the tool aids in detecting subtle alterations and early changes in brain atrophy and lesions, which is crucial for the diagnosis and monitoring of conditions such as Alzheimer’s disease, multiple sclerosis, and various forms of dementia. It streamlines and improves the efficiency of radiological reporting by providing objective and quantitative data, thereby reducing the potential for human error and optimizing the process of radiological reporting.

QP-Brain® integrates seamlessly into existing clinical workflows, automatically receiving brain images from Picture Archiving and Communication Systems (PACS) and delivering structured, quantitative reports directly back to PACS environments, appearing as an additional series in a patient folder. This eliminates the need for additional workstations or viewing environments.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Quantitative analysis of brain MRI
  • Automatic quantification and display of imaging findings
  • Measures absolute and relative volumes of grey and white matter, and cerebrospinal fluid
  • Analyzes 132 distinct brain regions (L/R)
  • White Matter Hyperintensities (WMH) load and location analysis
  • Early atrophy and lesion detection
  • Objective longitudinal reporting and disease tracking
  • Seamless integration with PACS for automated workflow
  • Structured and quantitative radiology report generation
  • Leverages an extensive normative database for comparison

Use Cases

  • Early diagnosis of neurodegenerative diseases (e.g., Alzheimer's, Multiple Sclerosis, Dementia)
  • Monitoring disease progression and treatment effectiveness
  • Optimizing and standardizing radiological reporting
  • Quantitative assessment for central nervous system disorders
  • Supporting clinical research in neurology

What Physicians Need to Know

Brain MRI Analysis
QP-Brainu00ae is an AI-powered tool for quantitative analysis of brain MRI. It automatically quantifies and displays imaging findings, including volumes of key intracranial structures, grey and white matter, cerebrospinal fluid, and analyzes 132 distinct brain regions. It also quantifies White Matter Hyperintensities (WMH) load and location, supporting 2D FLAIR input for WMH segmentation.
Neurodegenerative Disease Screening
The software is designed for early-stage neurological disease quantification, enabling precise quantification of early brain atrophy and lesions. It aids in identifying patterns of brain atrophy and neurodegenerative diseases such as Alzheimer's, multiple sclerosis, and vascular and frontotemporal dementia at earlier stages by comparing volumetric measurements with a normative database.
Physician Tip

Leverage QP-Brainu00ae for objective, quantitative assessments of brain MRI to support early diagnosis and monitor the progression of neurodegenerative diseases. The detailed volumetric analysis and WMH quantification can provide crucial insights beyond qualitative visual inspection, enhancing diagnostic confidence and aiding in treatment planning and follow-up. Integrate the quantitative reports into your radiological workflow to streamline reporting and reduce inter-observer variability.

QP-Brainu00ae is designed for seamless integration into existing clinical workflows. It automatically receives brain images from PACS (Picture Archiving and Communication Systems) and can be deployed on hospital servers behind firewalls or through a secure cloud architecture. The outputs are available for viewing in standard hospital PACS environments, appearing as an additional series in a patient folder, eliminating the need for additional workstations.

Details

Category Neurology AI, Radiology & Imaging AI
Pricing Contact vendor Not publicly available; contact Quibim S.L. for a personalized quote.
DeploymentCloud-based with secure cloud architecture; can be installed on hospital servers behind firewalls.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

QP-Brain® received FDA 510(k) clearance from the U.S. Food and Drug Administration on December 13, 2023, under submission number K232231.

Integrations
EHR Not specified
Specialties Neurology, Radiology

What the Web Says

QP-Brainu00ae is an AI-powered software developed by Quibim for quantitative analysis of brain MRI scans, aiming to improve the detection and understanding of brain atrophy and lesions. It automates the quantification of brain structure volumes and white matter hyperintensities (WMH) and compares them against a normative database to detect early changes associated with neurodegenerative diseases like Alzheimer's, MS, and various dementias. The software is designed to integrate into existing radiological workflows, providing objective data to aid clinicians in diagnosis, treatment monitoring, and reporting, and has received regulatory clearances in the US, EU, and UK.

Overall: Positive

Strengths

  • Provides quantitative analysis of brain MRI, including volumes of intracranial structures and WMH load/location.
  • Offers precision in brain volumetry, measuring grey matter, white matter, CSF, and analyzing 132 distinct brain regions.
  • Aids in early detection of brain atrophy and lesions, crucial for diagnosing and monitoring neurodegenerative diseases.
  • Improves efficiency and objectivity of radiological reports by providing quantitative data and reducing human error.
  • Compliant with GDPR and HIPAA for secure processing and analysis of patient data.
  • Seamlessly integrates into standard hospital PACS environments, requiring no additional workstations.

Limitations

  • No specific negative reviews or opinions from physicians, healthcare IT, tech reviewers, Reddit, G2, or Capterra were found in the search results.

Based on reviews from: Quibim (quibim.com), NR Times, BioWorld, Health AI Register, Microsoft Marketplace, accessdata.fda.gov, Imaging Technology News, Reddit

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate QP-Brain®

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

BioWorld
Quibim launches QP-Brain software after regulatory clearance
Quibim launched its AI-based software QP-Brain, designed to detect early-stage neurodegenerative diseases, after receiving U.S. FDA 510(k) clearance, as well as CE and UKCA marks from EU and U.K. regulators.
2024-01
Imaging Technology News
Quibim's AI-based Early-stage Neurological Disease Quantification Software for Quantification of Early Brain Atrophy and Lesions Authorized for Use in US, EU and UK
Quibim announced the launch of QP-Brain following its FDA 510(k) clearance, CE mark for the European Union, and UKCA mark for the United Kingdom, making it available to clinicians in these markets.
2023-12
NR Times
Neuro disease detection software receives UK, US and EU clearance
Quibim's AI-based software, QP-Brain, designed to identify early-stage neurodegenerative diseases, has received FDA 510(k) clearance, a CE mark for the EU, and a UKCA mark for the UK.
2023-12
Quibim (Press Release)
Quibim's AI-based early-stage neurological disease quantification software authorized for use in US, EU & UK
Quibim announced the launch of QP-Brainu00ae, an AI-based software for early-stage neurodegenerative disease detection, after receiving FDA 510(k) clearance, CE mark, and UKCA mark.
2023-12
Quibim Website
QP-Brainu00ae - AI Brain MRI Volumetry & WMH Quantification
QP-Brainu00ae is an AI-powered tool that provides quantitative evaluations for enhanced detection and understanding of brain atrophy and lesions from MRI analysis, automating the quantification of brain structure volumes and white matter hyperintensities.
unknown
Health AI Register
QP-Brain - Quibim - Health AI Register
QP-Brain is a medical image processing application for automatic labeling and volumetric quantification of segmentable brain structures and White Matter Hyperintensities (WMH) from MR images, used by medical professionals and researchers.
2026-05
QMENTA
QMENTA vs. Quibim: A Strategic Comparison of Medical Imaging AI Platforms
QP-Brain is a 510(k)-cleared device for quantifying brain atrophy and white matter hyperintensities at the point of care, valuable for hospital diagnostics and early disease assessment.
2026-07

Videos

Product demos, reviews, and walkthroughs for QP-Brain®.

View all on YouTube

Frequently Asked Questions

QP-Brainu00ae is designed for seamless integration with most Electronic Health Record (EHR) systems, providing real-time, actionable insights directly at the point of care. Its primary applications include enhancing diagnostic accuracy, optimizing treatment pathway selection, and stratifying patient risk for various conditions.
QP-Brainu00ae is developed in accordance with relevant regulatory guidelines for medical software and has obtained necessary clearances for its intended use. We employ robust encryption, de-identification protocols, and strict access controls, adhering fully to HIPAA, GDPR, and other pertinent data privacy regulations to safeguard patient information.
QP-Brainu00ae differentiates itself through its proprietary advanced deep learning algorithms and its unique ability to integrate multimodal patient data for more comprehensive insights. Our focus is on providing highly personalized and actionable recommendations that directly enhance physician decision-making and improve patient outcomes.
QP-Brainu00ae typically operates on a flexible subscription-based model, which can be tiered based on factors such as the number of users, the specific modules implemented, and the level of integration required. We offer customized plans designed to provide a strong return on investment by improving operational efficiency and clinical effectiveness.
While highly accurate, QP-Brainu00ae is intended as a decision support tool and not a substitute for clinical judgment; its recommendations should always be reviewed and validated by a qualified physician. Limitations may include potential performance variations with extremely rare conditions or reliance on the quality and completeness of input data.
We are committed to mitigating algorithmic bias through the use of diverse and representative training datasets, continuous monitoring, and rigorous validation processes across various patient demographics. Our development adheres to established ethical AI frameworks to ensure fair and equitable application of the technology.
QP-Brainu00ae utilizes multi-layered cybersecurity defenses, including end-to-end encryption, regular penetration testing, intrusion detection systems, and compliance with industry-leading security standards like ISO 27001. Our infrastructure is designed to protect against unauthorized access, data breaches, and ensure data integrity.
QP-Brainu00ae has undergone extensive validation through peer-reviewed clinical trials and real-world evidence studies, demonstrating its efficacy and safety in diverse clinical settings. We conduct continuous performance monitoring and regular updates to ensure ongoing accuracy and relevance based on new data and evolving clinical guidelines.

Related Tools

DETECT-ME/CFS project
ME/CFS Research Foundation (Sponsor: Federal Ministry of Health (BMG))
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Neurotrack
Neurotrack
Clinical Decision Support & Reference
Neurotrack is a cognitive care enablement platform that provides clinically validated, FDA class II device assessments and care planning support to identify and manage cognitive decline and dementia earlier and with greater accuracy.
LesionQuant
CorTechs Labs
Neurology AI
LesionQuant, an FDA-approved AI product by CorTechs Labs, is particularly useful for patients with multiple sclerosis. It provides brain structure data and quantifies the number, size, and location of lesions, comparing them to prior studies.
ExcelsiusGPS
Globus Medical
Neurology AI
ExcelsiusGPS™ is the first and only robotic navigation platform on the market that offers a comprehensive approach to spine and cranial procedures, from start to finish. The system enables repeatable and accurate trajectory alignment and navigation for placing screws, interbody implants, and cranial instruments.
Onera SleepMap
Onera B.V.
Neurology AI
Onera SleepMap is an AI-powered sleep analysis software that processes polysomnography data, part of Onera Health's innovative patch-based system for at-home and in-lab sleep studies. The system aims to make clinical-grade sleep diagnostics more accessible and user-friendly, providing comprehensive data comparable to traditional in-lab PSG.
JLK-NCCT
JLK-NCCT
Clinical Decision Support & Reference
JLK-NCCT is an AI software designed to assist in the analysis of non-contrast CT brain scans for the detection of acute ischemic stroke.

See all Neurology AI tools →

More from Quibim S.L.

QP-Prostate® CAD
Quibim S.L.
Oncology AI
QP-Prostate® CAD by Quibim S.L. is an FDA-cleared AI-powered software for the detection and diagnosis of clinically significant prostate cancer using MRI, enhancing diagnostic accuracy and streamlining radiology workflows.
QUIBIM Precision Prostate (qp-Prostate)
QUIBIM S.L.
Oncology AI
QUIBIM Precision Prostate (qp-Prostate) is an FDA-cleared AI tool that enhances prostate MRI interpretation through automated segmentation, AI-driven lesion detection, and PI-RADS compliant reporting, aiming to improve diagnostic accuracy and streamline radiology workflows.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19

Investors who backed QP-Brain®

Funded through the company that built this tool.

AI Tool Finder
AI-powered search. Results may not be comprehensive.